Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Finished Goods: 2016-2024

Historic Finished Goods for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $17.8 million.

  • Collegium Pharmaceutical's Finished Goods rose 23.13% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 23.13%. This contributed to the annual value of $17.8 million for FY2024, which is 17.12% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Finished Goods of $17.8 million as of FY2024, which was up 17.12% from $15.2 million recorded in FY2023.
  • Collegium Pharmaceutical's Finished Goods' 5-year high stood at $17.8 million during FY2024, with a 5-year trough of $11.0 million in FY2020.
  • Its 3-year average for Finished Goods is $16.4 million, with a median of $16.2 million in 2022.
  • Per our database at Business Quant, Collegium Pharmaceutical's Finished Goods spiked by 48.28% in 2020 and then dropped by 6.29% in 2023.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Finished Goods stood at $11.0 million in 2020, then increased by 15.43% to $12.7 million in 2021, then increased by 27.77% to $16.2 million in 2022, then fell by 6.29% to $15.2 million in 2023, then rose by 17.12% to $17.8 million in 2024.